Commercializationv1 · 10.24
From testing a patient's cancer to making their treatment ↗
At what quality, turnaround time and cost can patient-specific medicines be supplied repeatedly?
The company-reported phase 3 trial found two-year recurrence-free survival of 82.2% versus 70.0% after melanoma surgery. The expanded Tempus collaboration covers specimen collection and transfer, with sequencing subject to regulatory approvals.
- Phase 3 results reportedRecorded
- Assess regulation and supplyUnverified
- Commercial scale and costsUnverified
New question opened
Record phase 3 results and supply roles, and track patient-level manufacturing and delivery conditions.
NEXT CHECK
Regulatory decisions, specimen-to-delivery time, manufacturing success, per-patient costs and indication-specific outcomes.
Evidence: JCO Oncology Advances ↗Tempus ↗